Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 5/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6580474 | 0.88 | NOS3 (0.44) | FPR2CNR2NOS3NOS1NOS2 | |
| SCHEMBL5752076 | 0.88 | NOS3 (0.44) | FPR2CNR2NOS3NOS1NOS2 | |
| SCHEMBL5752847 | 0.84 | BACE1 (0.43) | FPR2BACE1CNR2BCHENOS3 | |
| SCHEMBL5753769 | 0.84 | CNR2 (0.61) | BACE1CNR2ALDH1A1PTPN1 | |
| SCHEMBL5752315 | 0.84 | CNR2 (0.45) | FPR2BACE1CNR2NOS3NOS1 | |
| SCHEMBL5753639 | 0.82 | MMP2 (0.46) | FPR2CNR2CTSLALDH1A1 | |
| SCHEMBL5753673 | 0.82 | FFAR2 (0.52) | FPR2BACE1CNR2ALDH1A1 | |
| SCHEMBL5751446 | 0.81 | CTSL (0.50) | CNR2CTSLNOS3NOS1NOS2 | |
| SCHEMBL5755551 | 0.80 | LMNA (0.49) | FPR2BACE1CNR2 | |
| SCHEMBL5751792 | 0.80 | LMNA (0.49) | FPR2BACE1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | FPR2 1918/4885BACE1 835/4885CNR2 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.